Back to Menu
Medullary Thyroid Carcinoma Treatment Modalities
1.Radical surgical treatment
The foundation of therapy: total thyroidectomy with central compartment dissection. For hereditary high-risk individuals, prophylactic thyroidectomy may be considered in early childhood.
2.Minimally invasive surgical treatment
Endoscopic techniques may be used in selected cases such as complex recurrence or mediastinal metastasis, reducing surgical trauma and facilitating recovery.
3.Multikinase inhibitor targeted therapy
Agents such as vandetanib and cabozantinib inhibit RET and other targets, helping control progression in advanced disease and prolong survival.
4.Highly selective RET inhibitor targeted therapy
Agents such as selpercatinib provide precise inhibition of RET alterations, with high efficacy and fewer adverse effects, and can address resistance.
5.Development of novel targeted agents
Clinical trials of next-generation RET inhibitors offer continued options to overcome drug resistance.
6.Precision imaging–guided management
Advanced molecular imaging can localize metastatic lesions more accurately and guide treatment decisions.
7.Local therapies
For oligoprogressive metastatic lesions (e.g., bone or liver), surgery, radiofrequency ablation, or stereotactic radiotherapy may be used to control symptoms and local disease.
8.Multidisciplinary collaborative model
An MDT team including head and neck surgery and medical oncology jointly determines optimal individualized treatment strategies.
9.Radiotherapy
Used as palliative treatment for unresectable residual or recurrent lesions and for relief of pain from bone metastases.
10.Chemotherapy
Conventional chemotherapy (e.g., dacarbazine) has low response rates and substantial toxicity and is generally reserved as a last-line option.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that although medullary thyroid carcinoma is rare, it is aggressive and prone to metastasis, posing a serious threat to life. Early diagnosis is a prerequisite for favorable outcomes. Current management has entered an era of individualized care based on MDT collaboration, integrating curative surgery, precision targeted therapy, and minimally invasive techniques. Adherence to standardized care and lifelong follow-up is fundamental to achieving long-term, high-quality survival.
Medullary Thyroid Carcinoma Treatment Modalities
1.Radical surgical treatment
The foundation of therapy: total thyroidectomy with central compartment dissection. For hereditary high-risk individuals, prophylactic thyroidectomy may be considered in early childhood.
2.Minimally invasive surgical treatment
Endoscopic techniques may be used in selected cases such as complex recurrence or mediastinal metastasis, reducing surgical trauma and facilitating recovery.
3.Multikinase inhibitor targeted therapy
Agents such as vandetanib and cabozantinib inhibit RET and other targets, helping control progression in advanced disease and prolong survival.
4.Highly selective RET inhibitor targeted therapy
Agents such as selpercatinib provide precise inhibition of RET alterations, with high efficacy and fewer adverse effects, and can address resistance.
5.Development of novel targeted agents
Clinical trials of next-generation RET inhibitors offer continued options to overcome drug resistance.
6.Precision imaging–guided management
Advanced molecular imaging can localize metastatic lesions more accurately and guide treatment decisions.
7.Local therapies
For oligoprogressive metastatic lesions (e.g., bone or liver), surgery, radiofrequency ablation, or stereotactic radiotherapy may be used to control symptoms and local disease.
8.Multidisciplinary collaborative model
An MDT team including head and neck surgery and medical oncology jointly determines optimal individualized treatment strategies.
9.Radiotherapy
Used as palliative treatment for unresectable residual or recurrent lesions and for relief of pain from bone metastases.
10.Chemotherapy
Conventional chemotherapy (e.g., dacarbazine) has low response rates and substantial toxicity and is generally reserved as a last-line option.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that although medullary thyroid carcinoma is rare, it is aggressive and prone to metastasis, posing a serious threat to life. Early diagnosis is a prerequisite for favorable outcomes. Current management has entered an era of individualized care based on MDT collaboration, integrating curative surgery, precision targeted therapy, and minimally invasive techniques. Adherence to standardized care and lifelong follow-up is fundamental to achieving long-term, high-quality survival.